Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Large Decrease in Short Interest

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 50,600 shares, a decrease of 29.8% from the February 13th total of 72,100 shares. Based on an average trading volume of 42,500 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.8% of the shares of the stock are sold short.

Kiora Pharmaceuticals Price Performance

NASDAQ KPRX traded up $0.05 during trading on Monday, reaching $3.29. The company’s stock had a trading volume of 14,494 shares, compared to its average volume of 33,050. The firm has a fifty day moving average of $3.54 and a 200 day moving average of $3.50. Kiora Pharmaceuticals has a one year low of $2.91 and a one year high of $6.48.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently raised its position in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC lifted its position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 200,221 shares of the company’s stock after purchasing an additional 3,670 shares during the quarter. ADAR1 Capital Management LLC owned 6.67% of Kiora Pharmaceuticals worth $661,000 at the end of the most recent quarter. 76.97% of the stock is owned by institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.